Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Gennex Laboratories Ltd (531739)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 531739 NSE: Pharmaceuticals & Drugs | Small Cap | Gennex Laboratories Share Price
₹8.02 -0.94 (-10.49%)
As on 30-Oct'26 16:59
Gennex Laboratories Ltd (531739)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 531739 NSE: Pharmaceuticals & Drugs | Small Cap | Gennex Laboratories Share Price
₹8.02 -0.94 (-10.49%)
As on 30-Oct'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹195 Cr.
Current Price
₹8
52-Week Low / High
₹7 / 17
TTM EPS
₹0.8
TTM Sales
₹178 Cr.
Book Value per Share
₹9.4
P/E Ratio
10.05
Lower than its 5-year historical median
Industry PE
52.9
Price to Book (P/B)
0.86
Lower than its 5-year historical median
Price to Sales (P/S)
1.09
Lower than its 5-year historical median
EV/EBITDA
7.46
Lower than its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
10.40%
Outperforms industry median
Return on Capital Employed (ROCE)
10.70%
In line with industry median
Return on Assets (ROA)
6.94%
Outperforms industry median
Operating Profit Margin
12.5%
Outperforms industry median
Net Profit Margin
12.14%
Outperforms industry median
Gross Profit Margin
13.4%
Outperforms industry median
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
26.73%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
29.64%
Net Profit Growth (1 Year)
Slowing versus 3-year growth rate
15.78%
Asset Quality
Promoter Holding
23.63%
Pledged shares (%) of Promoter's holding (%)
21.77%
Reserves
₹203 Cr.
Equity
₹24.3 Cr.
Face Value
₹1
All Time Low / High
₹0.22 / 29.00
Check Before You Invest
Quality
Not GoodValuation
UndervaluedCheck Valuation charts
Price Trend
Weak
Is Gennex Laboratories Ltd a good quality company?
Gennex Laboratories Ltd is a weak quality company, based on a inconsistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Gennex Laboratories Ltd performance compare with that of its Peers?
Revenue growth of Gennex Laboratories Ltd vs industry peers?
Gennex Laboratories Ltd revenue CAGR is 23.70%, compared to the industry median CAGR of 0.00%, indicating faster growth and gaining its market share.
Promoter shareholding and pledge status of Gennex Laboratories Ltd?
Promoters hold 23.63% of the Gennex Laboratories Ltd, with 21.77% of their stake pledged, indicating high pledge risk.
Stock return of Gennex Laboratories Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 1.6% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Gennex Laboratories Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 11.6% | 6.3% | 10.5% | 8.3% | 13.2% | 11.8% | 10.7% | 12.5% | 10.3% | 9.5% | - |
| Value Creation Index ⓘ | -0.2 | -0.6 | -0.3 | -0.4 | -0.1 | -0.2 | -0.2 | -0.1 | -0.3 | -0.3 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 41.9 | 43.8 | 55.8 | 55.6 | 59.7 | 61.2 | 65.1 | 66.8 | 94.6 | 120 | 129 |
| Sales YoY Gr. | - | 4.5% | 27.5% | -0.3% | 7.3% | 2.6% | 6.4% | 2.6% | 41.6% | 26.7% | - |
| Adj EPS ⓘ | 0.2 | 0.1 | 0.2 | 0.1 | 0.3 | 0.3 | 0.2 | 0.5 | 0.6 | 0.7 | 0.7 |
| YoY Gr. | - | -71.4% | 183.3% | -29.4% | 158.3% | -9.7% | -14.3% | 112.5% | 21.6% | 8.1% | - |
| BVPS (₹) ⓘ | 2.3 | 2.4 | 2.6 | 2.7 | 3 | 3.3 | 4.5 | 7.3 | 7.9 | 9 | 9.1 |
| Adj Net Profit ⓘ | 2.7 | 0.9 | 2.2 | 1.6 | 4.1 | 3.7 | 4.2 | 11.7 | 14 | 16.3 | 16 |
| Cash Flow from Ops. ⓘ | -0.1 | 3.2 | 1.9 | -1.7 | -1.4 | 6.6 | -14.5 | -33.4 | -9.5 | -40.2 | - |
| Debt/CF from Ops. ⓘ | -36.2 | 0.8 | 2.4 | -3 | -5.1 | 1.5 | -0.2 | -0.1 | -0.6 | -0.7 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 12.4% | 15% | 22.6% | 26.7% | ||||
| Adj EPS ⓘ | 13.8% | 16.7% | 40.8% | 8.1% | ||||
| BVPSⓘ | 16.2% | 24.4% | 26.4% | 14.1% | ||||
| Share Price | 1.9% | 4.1% | -10.3% | -51.2% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 9.2 | 2.7 | 6.7 | 4.7 | 10.7 | 8.7 | 6.9 | 9.4 | 7.9 | 8.1 | 7.3 |
| Op. Profit Mgn % ⓘ | 10.9 | 5.2 | 7.2 | 5.8 | 11 | 8.8 | 7 | 18.6 | 10.9 | 11.8 | 14.2 |
| Net Profit Mgn % ⓘ | 6.5 | 2 | 4 | 2.9 | 6.8 | 6 | 6.5 | 17.5 | 14.8 | 13.6 | 12.4 |
| Debt to Equity ⓘ | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 | 0 | 0 | 0 | 0.1 | - |
| Working Cap Days ⓘ | 185 | 203 | 161 | 184 | 204 | 213 | 249 | 436 | 435 | 431 | 325 |
| Cash Conv. Cycle ⓘ | 10 | 2 | 15 | 33 | 25 | 43 | 70 | 59 | 59 | 107 | 254 |
Valuation of Gennex Laboratories - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 23.87 | 21.79 | 17.43 | 17.43 | 17.42 | 21.77 | 21.77 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 42 | 44 | 56 | 56 | 60 | 61 | 66 | 87 | 138 | 173 |
| Operating Expenses ⓘ + | 37 | 42 | 52 | 52 | 53 | 56 | 61 | 70 | 121 | 151 |
| Operating Profit ⓘ | 5 | 2 | 4 | 3 | 7 | 5 | 5 | 17 | 17 | 22 |
| Operating Profit Margin (%) | 10.8% | 5.0% | 7.2% | 5.8% | 11.0% | 8.8% | 7.2% | 19.6% | 12.1% | 12.5% |
| Other Income ⓘ + | 0 | 1 | 1 | 1 | 1 | 1 | 4 | 5 | 10 | 9 |
| Interest ⓘ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 4 | 4 |
| Depreciation ⓘ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 3 |
| Profit Before Tax ⓘ | 3 | 1 | 3 | 3 | 5 | 5 | 6 | 16 | 21 | 23 |
| Tax ⓘ | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 2 |
| Profit After Tax | 3 | 1 | 2 | 2 | 4 | 4 | 5 | 13 | 18 | 21 |
| PAT Margin (%) | 6.5% | 1.9% | 4.0% | 3.3% | 6.8% | 6.4% | 7.5% | 15.2% | 13.1% | 12.1% |
| Adjusted EPS (₹) | 0.2 | 0.1 | 0.2 | 0.1 | 0.3 | 0.3 | 0.4 | 0.5 | 0.8 | 0.9 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 31 | 32 | 34 | 36 | 40 | 44 | 80 | 165 | 181 | 223 | |
| Debt + | 4 | 3 | 5 | 5 | 7 | 10 | 17 | 19 | 24 | 79 | |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 6 | 8 | 10 | |
| Trade Payables | 9 | 12 | 8 | 8 | 6 | 8 | 7 | 15 | 13 | 20 | |
| Others Liabilities ⓘ | 5 | 4 | 5 | 8 | 6 | 6 | 21 | 25 | 30 | 16 | |
| Total Liabilities ⓘ | 49 | 50 | 52 | 57 | 59 | 68 | 132 | 230 | 256 | 349 | |
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 16 | 16 | 16 | 15 | 14 | 14 | 74 | 56 | 60 | 61 | |
| CWIP ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 5 | 13 | |
| Investments ⓘ | 7 | 7 | 7 | 7 | 7 | 7 | 0 | 0 | 0 | 0 | |
| Inventories | 3 | 2 | 5 | 7 | 5 | 8 | 16 | 25 | 36 | 54 | |
| Trade Receivables | 10 | 10 | 10 | 6 | 8 | 11 | 9 | 18 | 14 | 44 | |
| Cash Equivalents | 1 | 1 | 3 | 1 | 1 | 8 | 15 | 61 | 56 | 52 | |
| Others Assets ⓘ | 13 | 14 | 10 | 21 | 24 | 20 | 18 | 68 | 85 | 125 | |
| Total Assets ⓘ | 49 | 50 | 52 | 57 | 59 | 68 | 132 | 230 | 256 | 349 | |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | -0 | 3 | 2 | -2 | -1 | 12 | 24 | -47 | -11 | -64 |
| Cash Flow From Investing Activity ⓘ + | -1 | -1 | -1 | -0 | -0 | -2 | -38 | 19 | 1 | -5 |
| Cash Flow From Financing Activity ⓘ + | 1 | -2 | 1 | -0 | 2 | -2 | 21 | 74 | 5 | 65 |
| Net Cash Flow ⓘ | -0 | 0 | 2 | -2 | 0 | 8 | 6 | 46 | -5 | -3 |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 8.74 | 2.67 | 6.77 | 5.34 | 10.71 | 9.39 | 7.95 | 10.77 | 10.49 | 10.4 |
| ROCE (%) | 10.91 | 6.31 | 10.52 | 8.36 | 13.24 | 11.82 | 10.19 | 13.64 | 12.49 | 10.7 |
| Asset Turnover Ratio | 0.88 | 0.95 | 1.17 | 1.1 | 1.1 | 1.03 | 0.72 | 0.54 | 0.64 | 0.65 |
| PAT to CFO Conversion(x) | -0 | 3 | 1 | -1 | -0.25 | 3 | 4.8 | -3.62 | -0.61 | -3.05 |
| Working Capital Days | ||||||||||
| Receivable Days | 86.40 | 80.10 | 63.50 | 50.80 | 40 | 53.10 | 52.70 | 50.50 | 37.40 | 53.50 |
| Inventory Days | 24.30 | 20.20 | 23.30 | 38.90 | 35.70 | 35.70 | 59.50 | 75.90 | 71.40 | 83.20 |
| Payable Days | 144.30 | 147.60 | 113.40 | 88.40 | 71.90 | 65.60 | 67.80 | 83.20 | 53.30 | 47.50 |
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Annual reports
No annual reports available.
Concalls
No concalls available.
Gennex Laboratories Ltd FAQs
The current trading price of Gennex Laboratories on 30-Oct-2026 16:59 is ₹8.02.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 29-Oct-2026 the market cap of Gennex Laboratories stood at ₹194.8 Cr
The latest P/E ratio of Gennex Laboratories as of 29-Oct-2026 is 12.23.
The latest P/B ratio of Gennex Laboratories as of 29-Oct-2026 is 0.88.
The 52-week high of Gennex Laboratories is ₹16.99 and the 52-week low is ₹7.05.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Gennex Laboratories is ₹129 ( Cr.) .
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Gennex Laboratories Ltd is a below average quality company.
The key valuation ratios of Gennex Laboratories Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Gennex Laboratories Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
About Gennex Laboratories Ltd
Gennex Laboratories (formerly Prudential Pharmaceuticals) is a public limited company established in the year 1995 and has been engaged in the manufacturing of bulk drugs and intermediates. The company started as one of the leading manufacturer and exporter of bulk drugs and intermediates. Quality is the strength of the company and major part of its finished products are exported to various countries viz. Germany, United Kingdom, Spain, Singapore, Canada, Switzerland, Iran, Bangladesh, Pakistan and other major countries. Gennex Laboratories has diversified its activities to biotech products in order to have better prospects and opportunities for the company for expanding its bussiness activities and to meet the marketing requirements.
The company had commenced its commercial operations of Guaifenesin in November, 1995 and in a span of about one and half years, it was able to capture about 70% of the domestic market mainly due to the impeccable quality, aggressive marketing strategies, cost effective manufacturing and efficient distribution cum market penetration. It has also established itself fairly well in the export market and recognized well by many end-users and trading giants of international market.
The company has catered to countries like USA, Mexico, Spain and Germany and the quality has been accepted and appreciated extremely well with all the customers. Several customers have evinced interest on long-term tie-ups. Slowly but surely, the company is constantly expanding its reach to USA and European markets and it has been receiving very encouraging enquiries from prospective customers based on quality recommendations by existing customers. The company’s headquarters is situated in the heart of the city and the factory is situated at Survey No 133, IDA Bollaram, Jinnaram Mandal, Medak District-502 325, Andhra Pradesh, India. The factory occupies a total land area of 8,000 square meters. The total building floor space is1,945 square meters. The storage space is 500 square meters. The central lab has a floor space of 225 square meters.
Products of the company:
- Guaiphenesin
- Methocarbamol
- Fluconazole
- Phenazopyridine
Certification:
- Gennex Laboratories is an ISO 9001: 2008 approved company and obtained GMP Certification from the Central Drug Authority.
- The company is also planning for ISO 14001: 2002 certification and OHSHAS 18000 to ensure its products are more widely accepted in the international market.
You have 3 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now